Day Zero Diagnostics Wins Disruptive Technology Award at the 2021 AACC Annual Scientific Meeting
BOSTON, Sept. 30, 2021 /PRNewswire-PRWeb/ --Day Zero Diagnostics, Inc., an infectious disease diagnostics company harnessing the power of whole-genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, has won the 2021 Disruptive Technology Award from The American Association for Clinical Chemistry (AACC) and the Audience Choice Award.
- BOSTON, Sept. 30, 2021 /PRNewswire-PRWeb/ --Day Zero Diagnostics, Inc., an infectious disease diagnostics company harnessing the power of whole-genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, has won the 2021 Disruptive Technology Award from The American Association for Clinical Chemistry (AACC) and the Audience Choice Award.
- The Disruptive Technology Award recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high-quality testing.
- "We are thrilled to be recognized by the AACC as a disruptive technology with the potential to transform patient care," said Jong Lee, CEO of Day Zero Diagnostics.
- Day Zero Diagnostics was founded in 2016 by a team of clinicians and scientists from Harvard University and Massachusetts General Hospital.